<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34681883</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>20</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Histone Deacetylase Inhibition Regulates Lipid Homeostasis in a Mouse Model of Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">11224</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms222011224</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an incurable and fatal neurodegenerative disorder of the motor system. While the etiology is still incompletely understood, defects in metabolism act as a major contributor to the disease progression. Recently, histone deacetylase (HDAC) inhibition using ACY-738 has been shown to restore metabolic alterations in the spinal cord of a FUS mouse model of ALS, which was accompanied by a beneficial effect on the motor phenotype and survival. In this study, we investigated the specific effects of HDAC inhibition on lipid metabolism using untargeted lipidomic analysis combined with transcriptomic analysis in the spinal cord of FUS mice. We discovered that symptomatic FUS mice recapitulate lipid alterations found in ALS patients and in the SOD1 mouse model. Glycerophospholipids, sphingolipids, and cholesterol esters were most affected. Strikingly, HDAC inhibition mitigated lipid homeostasis defects by selectively targeting glycerophospholipid metabolism and reducing cholesteryl esters accumulation. Therefore, our data suggest that HDAC inhibition is a potential new therapeutic strategy to modulate lipid metabolism defects in ALS and potentially other neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burg</LastName><ForeName>Thibaut</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8788-2936</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology, Leuven Brain Institute, KU Leuven-University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossaert</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology, Leuven Brain Institute, KU Leuven-University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moisse</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology, Leuven Brain Institute, KU Leuven-University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4010-2357</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology, Leuven Brain Institute, KU Leuven-University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Den Bosch</LastName><ForeName>Ludo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0104-4067</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology, Leuven Brain Institute, KU Leuven-University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>577668</GrantID><Agency>Muscular Dystrophy Association</Agency><Country/></Grant><Grant><GrantID>00099187</GrantID><Agency>Fondation Thierry Latran</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599551">FUS protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006877">Hydroxamic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C583720">N-hydroxy-2-(1-phenylcycloproylamino)pyrimidine-5-carboxamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056572" MajorTopicYN="N">Histone Deacetylase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006877" MajorTopicYN="N">Hydroxamic Acids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081362" MajorTopicYN="N">Lipidomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">HDAC inhibitors</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">epigenetic</Keyword><Keyword MajorTopicYN="N">glycerophospholipids</Keyword><Keyword MajorTopicYN="N">histone deacetylase</Keyword><Keyword MajorTopicYN="N">lipidomic</Keyword><Keyword MajorTopicYN="N">metabolism</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34681883</ArticleId><ArticleId IdType="pmc">PMC8541517</ArticleId><ArticleId IdType="doi">10.3390/ijms222011224</ArticleId><ArticleId IdType="pii">ijms222011224</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett S.A., Tanaz R., Cobos S.N., Torrente M.P. Epigenetics in amyotrophic lateral sclerosis: A role for histone post-translational modifications in neurodegenerative disease. Transl. Res. 2019;204:19&#x2013;30. doi: 10.1016/j.trsl.2018.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2018.10.002</ArticleId><ArticleId IdType="pmc">PMC6331271</ArticleId><ArticleId IdType="pubmed">30391475</ArticleId></ArticleIdList></Reference><Reference><Citation>Paez-Colasante X., Figueroa-Romero C., Sakowski S.A., Goutman S.A., Feldman E.L. Amyotrophic lateral sclerosis: Mechanisms and therapeutics in the epigenomic era. Nat. Rev. Neurol. 2015;11:266&#x2013;279. doi: 10.1038/nrneurol.2015.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.57</ArticleId><ArticleId IdType="pubmed">25896087</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdone L., Caserta M., Mauro E.D. Role of histone acetylation in the control of gene expression. Biochem. Cell Biol. 2005;83:344&#x2013;353. doi: 10.1139/o05-041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/o05-041</ArticleId><ArticleId IdType="pubmed">15959560</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruneteau G., Simonet T., Bauche S., Mandjee N., Malfatti E., Girard E., Tanguy M.L., Behin A., Khiami F., Sariali E., et al. Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: Potential role in reinnervation ability and disease progression. Brain. 2013;136:2359&#x2013;2368. doi: 10.1093/brain/awt164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt164</ArticleId><ArticleId IdType="pubmed">23824486</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossaert E., Pollari E., Jaspers T., Van Helleputte L., Jarpe M., Van Damme P., De Bock K., Moisse M., Van Den Bosch L. Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model. Acta Neuropathol. Commun. 2019;7:107. doi: 10.1186/s40478-019-0750-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0750-2</ArticleId><ArticleId IdType="pmc">PMC6612190</ArticleId><ArticleId IdType="pubmed">31277703</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouaux C., Jokic N., Mbebi C., Boutillier S., Loeffler J.P., Boutillier A.L. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 2003;22:6537&#x2013;6549. doi: 10.1093/emboj/cdg615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/cdg615</ArticleId><ArticleId IdType="pmc">PMC291810</ArticleId><ArticleId IdType="pubmed">14657026</ArticleId></ArticleIdList></Reference><Reference><Citation>Valle C., Salvatori I., Gerbino V., Rossi S., Palamiuc L., Ren&#xe9; F., Carr&#xec; M. Tissue-specific deregulation of selected HDACs characterizes ALS progression in mouse models: Pharmacological characterization of SIRT1 and SIRT2 pathways. Cell Death Dis. 2014;5:e1296. doi: 10.1038/cddis.2014.247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.247</ArticleId><ArticleId IdType="pmc">PMC4611720</ArticleId><ArticleId IdType="pubmed">24946089</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna S., Esposito S., Masala A., Sini P., Nieddu G., Galioto M., Fais M., Iaccarino C., Cestra G., Crosio C. HDAC1 inhibition ameliorates TDP-43-induced cell death in vitro and in vivo. Cell Death Dis. 2020;11:369. doi: 10.1038/s41419-020-2580-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-2580-3</ArticleId><ArticleId IdType="pmc">PMC7224392</ArticleId><ArticleId IdType="pubmed">32409664</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen C., Schmalbach S., Boeselt S., Sarlette A., Dengler R., Petri S. Differential Histone Deacetylase mRNA Expression Patterns in Amyotrophic Lateral Sclerosis. J. Neuropathol. Exp. Neurol. 2010;69:573&#x2013;581. doi: 10.1097/NEN.0b013e3181ddd404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181ddd404</ArticleId><ArticleId IdType="pubmed">20467334</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingl Y.E., Pakravan D., Van Den Bosch L. Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis. Br. J. Pharmacol. 2021;178:1353&#x2013;1372. doi: 10.1111/bph.15217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15217</ArticleId><ArticleId IdType="pubmed">32726472</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Naujock M., Fumagalli L., Vandoorne T., Baatsen P., Boon R., Ordovas L., Patel A., Welters M., Vanwelden T., et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Commun. 2017;8:861. doi: 10.1038/s41467-017-00911-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00911-y</ArticleId><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittlau K.S., Krasnow E.N., Fumagalli L., Vandoorne T., Baatsen P., Kerstens A., Giacomazzi G., Pavie B., Rossaert E., Beckers J., et al. Human motor units in microfluidic devices are impaired by FUS mutations and improved by HDAC6 inhibition. Stem Cell Rep. 2021;16:2213&#x2013;2227. doi: 10.1016/j.stemcr.2021.03.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2021.03.029</ArticleId><ArticleId IdType="pmc">PMC8452598</ArticleId><ArticleId IdType="pubmed">33891869</ArticleId></ArticleIdList></Reference><Reference><Citation>Taes I., Timmers M., Hersmus N., Bento-Abreu A., Van Den Bosch L., Van Damme P., Auwerx J., Robberecht W. Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum. Mol. Genet. 2013;22:1783&#x2013;1790. doi: 10.1093/hmg/ddt028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt028</ArticleId><ArticleId IdType="pubmed">23364049</ArticleId></ArticleIdList></Reference><Reference><Citation>Pigna E., Simonazzi E., Sanna K., Bernadzki K.M., Proszynski T., Heil C., Palacios D., Adamo S., Moresi V. Histone deacetylase 4 protects from denervation and skeletal muscle atrophy in a murine model of amyotrophic lateral sclerosis. EBioMedicine. 2019;40:717&#x2013;732. doi: 10.1016/j.ebiom.2019.01.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.01.038</ArticleId><ArticleId IdType="pmc">PMC6414308</ArticleId><ArticleId IdType="pubmed">30713114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuta R., Larochelle N., Fernandez M., Pal A., Minotti S., Tibshirani M., St Louis K., Gentil B.J., Nalbantoglu J.N., Hermann A., et al. Depending on the stress, histone deacetylase inhibitors act as heat shock protein co-inducers in motor neurons and potentiate arimoclomol, exerting neuroprotection through multiple mechanisms in ALS models. Cell Stress Chaperones. 2020;25:173&#x2013;191. doi: 10.1007/s12192-019-01064-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-019-01064-1</ArticleId><ArticleId IdType="pmc">PMC6985055</ArticleId><ArticleId IdType="pubmed">31900865</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazal R., Boeynaems S., Swijsen A., De Decker M., Fumagalli L., Moisse M., Vanneste J., Guo W., Boon R., Vercruysse T. HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutations. EMBO J. 2021;40:e106177. doi: 10.15252/embj.2020106177.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106177</ArticleId><ArticleId IdType="pmc">PMC8013789</ArticleId><ArticleId IdType="pubmed">33694180</ArticleId></ArticleIdList></Reference><Reference><Citation>Benoy V., Van den Berghe P., Jarpe M., Van Damme P., Robberecht W., Van Den Bosch L. Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease. Neurotherapeutics. 2017;14:417&#x2013;428. doi: 10.1007/s13311-016-0501-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0501-z</ArticleId><ArticleId IdType="pmc">PMC5398982</ArticleId><ArticleId IdType="pubmed">27957719</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochems J., Boulden J., Lee B.G., Blendy J.A., Jarpe M., Mazitschek R., Van Duzer J.H., Jones S., Berton O. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology. 2014;39:389&#x2013;400. doi: 10.1038/npp.2013.207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2013.207</ArticleId><ArticleId IdType="pmc">PMC3870780</ArticleId><ArticleId IdType="pubmed">23954848</ArticleId></ArticleIdList></Reference><Reference><Citation>Majid T., Griffin D., Criss Z., 2nd, Jarpe M., Pautler R.G. Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer&#x2019;s disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice. Alzheimers Dement. 2015;1:170&#x2013;181. doi: 10.1016/j.trci.2015.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2015.08.001</ArticleId><ArticleId IdType="pmc">PMC5975056</ArticleId><ArticleId IdType="pubmed">29854936</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell J.C., McGoldrick P., Vance C., Hortobagyi T., Sreedharan J., Rogelj B., Tudor E.L., Smith B.N., Klasen C., Miller C.C., et al. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol. 2013;125:273&#x2013;288. doi: 10.1007/s00401-012-1043-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1043-z</ArticleId><ArticleId IdType="pmc">PMC3549237</ArticleId><ArticleId IdType="pubmed">22961620</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Beltran L.C., Godoy-Corchuelo J.M., Losa-Fontangordo M., Williams D., Matias-Guiu J., Corrochano S. A Transcriptomic Meta-Analysis Shows Lipid Metabolism Dysregulation as an Early Pathological Mechanism in the Spinal Cord of SOD1 Mice. Int. J. Mol. Sci. 2021;22:9553. doi: 10.3390/ijms22179553.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22179553</ArticleId><ArticleId IdType="pmc">PMC8431303</ArticleId><ArticleId IdType="pubmed">34502460</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.O., Chia R., Miller D.E., Li R., Kumaran R., Abramzon Y., Alahmady N., Renton A.E., Topp S.D., Gibbs J.R., et al. Association of Variants in the SPTLC1 Gene with Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurol. 2021;78:1236&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406220</ArticleId><ArticleId IdType="pubmed">34459874</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol J., Jove M., Povedano M., Sproviero W., Dominguez R., Pinol-Ripoll G., Romero-Guevara R., Hye A., Al-Chalabi A., Torres P., et al. Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression. Brain Commun. 2021;3:fcab143. doi: 10.1093/braincomms/fcab143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab143</ArticleId><ArticleId IdType="pmc">PMC8361390</ArticleId><ArticleId IdType="pubmed">34396104</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracey T.J., Kirk S.E., Steyn F.J., Ngo S.T. The role of lipids in the central nervous system and their pathological implications in amyotrophic lateral sclerosis. Semin. Cell Dev. Biol. 2020;112:69&#x2013;81. doi: 10.1016/j.semcdb.2020.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2020.08.012</ArticleId><ArticleId IdType="pubmed">32962914</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A., Croixmarie V., Bouscary A., Mosbach A., Keime C., Boursier-Neyret C., Walter B., Spedding M., Loeffler J.P. Sphingolipid Metabolism Is Dysregulated at Transcriptomic and Metabolic Levels in the Spinal Cord of an Animal Model of Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2017;10:433. doi: 10.3389/fnmol.2017.00433.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00433</ArticleId><ArticleId IdType="pmc">PMC5758557</ArticleId><ArticleId IdType="pubmed">29354030</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., Veyrat-Durebex C., Bocca C., Patin F., Vourc&#x2019;h P., Kouassi Nzoughet J., Lenaers G., Andres C.R., Simard G., Corcia P., et al. Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS. Sci. Rep. 2017;7:17652. doi: 10.1038/s41598-017-17389-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-17389-9</ArticleId><ArticleId IdType="pmc">PMC5732162</ArticleId><ArticleId IdType="pubmed">29247199</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves-Filho A.B., Pinto I.F.D., Dantas L.S., Xavier A.M., Inague A., Faria R.L., Medeiros M.H.G., Glezer I., Yoshinaga M.Y., Miyamoto S. Alterations in lipid metabolism of spinal cord linked to amyotrophic lateral sclerosis. Sci. Rep. 2019;9:11642. doi: 10.1038/s41598-019-48059-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48059-7</ArticleId><ArticleId IdType="pmc">PMC6691112</ArticleId><ArticleId IdType="pubmed">31406145</ArticleId></ArticleIdList></Reference><Reference><Citation>Veyrat-Durebex C., Bris C., Codron P., Bocca C., Chupin S., Corcia P., Vourc&#x2019;h P., Hergesheimer R., Cassereau J., Funalot B., et al. Metabo-lipidomics of Fibroblasts and Mitochondrial-Endoplasmic Reticulum Extracts from ALS Patients Shows Alterations in Purine, Pyrimidine, Energetic, and Phospholipid Metabolisms. Mol. Neurobiol. 2019;56:5780&#x2013;5791. doi: 10.1007/s12035-019-1484-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1484-7</ArticleId><ArticleId IdType="pubmed">30680691</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge J.C., Jensen E.H., Yu J., Sardi S.P., Bialas A.R., Taksir T.V., Bangari D.S., Shihabuddin L.S. Neutral Lipid Cacostasis Contributes to Disease Pathogenesis in Amyotrophic Lateral Sclerosis. J. Neurosci. 2020;40:9137&#x2013;9147. doi: 10.1523/JNEUROSCI.1388-20.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1388-20.2020</ArticleId><ArticleId IdType="pmc">PMC7673008</ArticleId><ArticleId IdType="pubmed">33051352</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge J.C., Treleaven C.M., Pacheco J., Cooper S., Bao C., Abraham M., Cromwell M., Sardi S.P., Chuang W.L., Sidman R.L., et al. Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2015;112:8100&#x2013;8105. doi: 10.1073/pnas.1508767112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1508767112</ArticleId><ArticleId IdType="pmc">PMC4491749</ArticleId><ArticleId IdType="pubmed">26056266</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A., Croixmarie V., Priestman D.A., Rosenbohm A., Dirrig-Grosch S., D&#x2019;Ambra E., Huebecker M., Hussain G., Boursier-Neyret C., Echaniz-Laguna A., et al. Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase. Hum. Mol. Genet. 2015;24:7390&#x2013;7405. doi: 10.1093/hmg/ddv439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv439</ArticleId><ArticleId IdType="pmc">PMC4664174</ArticleId><ArticleId IdType="pubmed">26483191</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B., Desport J.C., Kajeu P., Jesus P., Nicolaud B., Nicol M., Preux P.M., Couratier P. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J. Neurol. Neurosurg. Psychiatry. 2011;82:628&#x2013;634. doi: 10.1136/jnnp.2010.211474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.211474</ArticleId><ArticleId IdType="pubmed">21097551</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindauer E., Dupuis L., Muller H.P., Neumann H., Ludolph A.C., Kassubek J. Adipose Tissue Distribution Predicts Survival in Amyotrophic Lateral Sclerosis. PLoS ONE. 2013;8:e67783. doi: 10.1371/journal.pone.0067783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0067783</ArticleId><ArticleId IdType="pmc">PMC3694869</ArticleId><ArticleId IdType="pubmed">23826340</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Corcia P., Fergani A., De Aguilar J.-L.G., Bonnefont-Rousselot D., Bittar R., Seilhean D., Hauw J.-J., Lacomblez L., Loeffler J.-P. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004&#x2013;1009. doi: 10.1212/01.wnl.0000285080.70324.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Deng J., Jaffa M., Cudkowicz M.E., Wills A.M. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;44:20&#x2013;24. doi: 10.1002/mus.22114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22114</ArticleId><ArticleId IdType="pmc">PMC4441750</ArticleId><ArticleId IdType="pubmed">21607987</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouscary A., Quessada C., Mosbach A., Callizot N., Spedding M., Loeffler J.P., Henriques A. Ambroxol Hydrochloride Improves Motor Functions and Extends Survival in a Mouse Model of Familial Amyotrophic Lateral Sclerosis. Front. Pharm. 2019;10:883. doi: 10.3389/fphar.2019.00883.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00883</ArticleId><ArticleId IdType="pmc">PMC6692493</ArticleId><ArticleId IdType="pubmed">31447678</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Veen J.N., Kennelly J.P., Wan S., Vance J.E., Vance D.E., Jacobs R.L. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim. Biophys. Acta Biomembr. 2017;1859:1558&#x2013;1572. doi: 10.1016/j.bbamem.2017.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2017.04.006</ArticleId><ArticleId IdType="pubmed">28411170</ArticleId></ArticleIdList></Reference><Reference><Citation>Molenaar M.R., Jeucken A., Wassenaar T.A., van de Lest C.H., Brouwers J.F., Helms J.B. LION/web: A web-based ontology enrichment tool for lipidomic data analysis. GigaScience. 2019;8:giz061. doi: 10.1093/gigascience/giz061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gigascience/giz061</ArticleId><ArticleId IdType="pmc">PMC6541037</ArticleId><ArticleId IdType="pubmed">31141612</ArticleId></ArticleIdList></Reference><Reference><Citation>Desvergne B., Michalik L., Wahli W. Transcriptional regulation of metabolism. Physiol. Rev. 2006;86:465&#x2013;514. doi: 10.1152/physrev.00025.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00025.2005</ArticleId><ArticleId IdType="pubmed">16601267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo-Ruiz I., Medina M.A., Martinez-Poveda B. From Food to Genes: Transcriptional Regulation of Metabolism by Lipids and Carbohydrates. Nutrients. 2021;13:1513. doi: 10.3390/nu13051513.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13051513</ArticleId><ArticleId IdType="pmc">PMC8145205</ArticleId><ArticleId IdType="pubmed">33946267</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M., Sato Y., Kawashima M., Furumichi M., Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44:D457&#x2013;D462. doi: 10.1093/nar/gkv1070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv1070</ArticleId><ArticleId IdType="pmc">PMC4702792</ArticleId><ArticleId IdType="pubmed">26476454</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler R.G., Pedersen W.A., Camandola S., Rothstein J.D., Mattson M.P. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann. Neurol. 2002;52:448&#x2013;457. doi: 10.1002/ana.10312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10312</ArticleId><ArticleId IdType="pubmed">12325074</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y., Rusznak Z., Herculano-Houzel S., Watson C., Paxinos G. Cellular composition characterizing postnatal development and maturation of the mouse brain and spinal cord. Brain Struct. Funct. 2013;218:1337&#x2013;1354. doi: 10.1007/s00429-012-0462-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00429-012-0462-x</ArticleId><ArticleId IdType="pubmed">23052551</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum-Loudeac J., Anderson G., Wilson M.J. Age and Sex-Related Changes to Gene Expression in the Mouse Spinal Cord. J. Mol. Neurosci. 2019;69:419&#x2013;432. doi: 10.1007/s12031-019-01371-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-019-01371-3</ArticleId><ArticleId IdType="pubmed">31267314</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge J.C. Lipid Involvement in Neurodegenerative Diseases of the Motor System: Insights from Lysosomal Storage Diseases. Front. Mol. Neurosci. 2017;10:356. doi: 10.3389/fnmol.2017.00356.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00356</ArticleId><ArticleId IdType="pmc">PMC5675881</ArticleId><ArticleId IdType="pubmed">29163032</ArticleId></ArticleIdList></Reference><Reference><Citation>Hishikawa D., Hashidate T., Shimizu T., Shindou H. Diversity and function of membrane glycerophospholipids generated by the remodeling pathway in mammalian cells. J. Lipid Res. 2014;55:799&#x2013;807. doi: 10.1194/jlr.R046094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R046094</ArticleId><ArticleId IdType="pmc">PMC3995458</ArticleId><ArticleId IdType="pubmed">24646950</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S.T., Ramesh T., Toh X.R., Nguyen L.N. Emerging roles of lysophospholipids in health and disease. Prog. Lipid Res. 2020;80:101068. doi: 10.1016/j.plipres.2020.101068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plipres.2020.101068</ArticleId><ArticleId IdType="pubmed">33068601</ArticleId></ArticleIdList></Reference><Reference><Citation>Falabella M., Vernon H.J., Hanna M.G., Claypool S.M., Pitceathly R.D.S. Cardiolipin, Mitochondria, and Neurological Disease. Trends Endocrinol. Metab. 2021;32:224&#x2013;237. doi: 10.1016/j.tem.2021.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2021.01.006</ArticleId><ArticleId IdType="pmc">PMC8277580</ArticleId><ArticleId IdType="pubmed">33640250</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance J.E. MAM (mitochondria-associated membranes) in mammalian cells: Lipids and beyond. Biochim. Biophys. Acta. 2014;1841:595&#x2013;609. doi: 10.1016/j.bbalip.2013.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2013.11.014</ArticleId><ArticleId IdType="pubmed">24316057</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgi C., Missiroli S., Patergnani S., Duszynski J., Wieckowski M.R., Pinton P. Mitochondria-associated membranes: Composition, molecular mechanisms, and physiopathological implications. Antioxid. Redox Signal. 2015;22:995&#x2013;1019. doi: 10.1089/ars.2014.6223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2014.6223</ArticleId><ArticleId IdType="pubmed">25557408</ArticleId></ArticleIdList></Reference><Reference><Citation>Parakh S., Atkin J.D. The Mitochondrial-associated ER membrane (MAM) compartment and its dysregulation in Amyotrophic Lateral Sclerosis (ALS) Semin. Cell Dev. Biol. 2021;112:105&#x2013;113. doi: 10.1016/j.semcdb.2021.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2021.02.002</ArticleId><ArticleId IdType="pubmed">33707063</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica R., De Vos K.J., Paillusson S., Mueller S., Sancho R.M., Lau K.F., Vizcay-Barrena G., Lin W.L., Xu Y.F., Lewis J., et al. ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. Nat. Commun. 2014;5:3996. doi: 10.1038/ncomms4996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4996</ArticleId><ArticleId IdType="pmc">PMC4046113</ArticleId><ArticleId IdType="pubmed">24893131</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S., Ilieva H., Tamada H., Nomura H., Komine O., Endo F., Jin S., Mancias P., Kiyama H., Yamanaka K. Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR1- and SOD1-linked ALS. EMBO Mol. Med. 2016;8:1421&#x2013;1437. doi: 10.15252/emmm.201606403.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606403</ArticleId><ArticleId IdType="pmc">PMC5167132</ArticleId><ArticleId IdType="pubmed">27821430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard-Marissal N., Chrast R., Schneider B.L. Endoplasmic reticulum and mitochondria in diseases of motor and sensory neurons: A broken relationship? Cell Death Dis. 2018;9:333. doi: 10.1038/s41419-017-0125-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-017-0125-1</ArticleId><ArticleId IdType="pmc">PMC5832431</ArticleId><ArticleId IdType="pubmed">29491369</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica R., Paillusson S., Gomez-Suaga P., Mitchell J.C., Lau D.H., Gray E.H., Sancho R.M., Vizcay-Barrena G., De Vos K.J., Shaw C.E., et al. ALS/FTD-associated FUS activates GSK-3beta to disrupt the VAPB-PTPIP51 interaction and ER-mitochondria associations. EMBO Rep. 2016;17:1326&#x2013;1342. doi: 10.15252/embr.201541726.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201541726</ArticleId><ArticleId IdType="pmc">PMC5007559</ArticleId><ArticleId IdType="pubmed">27418313</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman K.M., Brink L.E., Rodriguez-Bey G., Bodnar R.J., Kuang L., Xing B., Sullivan M., Park H.J., Koppes E., Zhu H., et al. Conditional depletion of Fus in oligodendrocytes leads to motor hyperactivity and increased myelin deposition associated with Akt and cholesterol activation. Glia. 2020;68:2040&#x2013;2056. doi: 10.1002/glia.23825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23825</ArticleId><ArticleId IdType="pmc">PMC7772959</ArticleId><ArticleId IdType="pubmed">32187401</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho W.Y., Chang J.C., Lim K., Cazenave-Gassiot A., Nguyen A.T., Foo J.C., Muralidharan S., Viera-Ortiz A., Ong S.J.M., Hor J.H., et al. TDP-43 mediates SREBF2-regulated gene expression required for oligodendrocyte myelination. J. Cell Biol. 2021;220:e201910213. doi: 10.1083/jcb.201910213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201910213</ArticleId><ArticleId IdType="pmc">PMC8348376</ArticleId><ArticleId IdType="pubmed">34347016</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez-Nu&#xf1;ez O., Jov&#xe9; M., Torres P., Sol J., Fontdevila L., Romero-Guevara R., Andr&#xe9;s-Benito P., Ayala V., Rossi C., Boada J., et al. Nuclear lipidome is altered in amyotrophic lateral sclerosis: A pilot study. J. Neurochem. 2021;158:482&#x2013;499. doi: 10.1111/jnc.15373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15373</ArticleId><ArticleId IdType="pubmed">33905537</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschallinger J., Iram T., Zardeneta M., Lee S.E., Lehallier B., Haney M.S., Pluvinage J.V., Mathur V., Hahn O., Morgens D.W., et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat. Neurosci. 2020;23:194&#x2013;208. doi: 10.1038/s41593-019-0566-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0566-1</ArticleId><ArticleId IdType="pmc">PMC7595134</ArticleId><ArticleId IdType="pubmed">31959936</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Cheng S., Lin Q., Cao W., Yang J., Zhang M., Shen A., Zhang W., Xia Y., Ma X., et al. Single-cell lipidomics with high structural specificity by mass spectrometry. Nat. Commun. 2021;12:2869. doi: 10.1038/s41467-021-23161-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23161-5</ArticleId><ArticleId IdType="pmc">PMC8129106</ArticleId><ArticleId IdType="pubmed">34001877</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejido C., Pakravan D., Bosch L.V.D. Potential Therapeutic Role of HDAC Inhibitors in FUS-ALS. Front. Mol. Neurosci. 2021;14:686995. doi: 10.3389/fnmol.2021.686995.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2021.686995</ArticleId><ArticleId IdType="pmc">PMC8380926</ArticleId><ArticleId IdType="pubmed">34434087</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W.-Y., Pan L., Su S.C., Quinn E.J., Sasaki M., Jimenez J.C., Mackenzie I.R., Huang E.J., Tsai L.-H. Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons. Nat. Neurosci. 2013;16:1383&#x2013;1391. doi: 10.1038/nn.3514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3514</ArticleId><ArticleId IdType="pmc">PMC5564396</ArticleId><ArticleId IdType="pubmed">24036913</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani M., Zhao B., Gentil B.J., Minotti S., Marques C., Keith J., Rogaeva E., Zinman L., Rouaux C., Robertson J., et al. Dysregulation of chromatin remodelling complexes in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2017;26:4142&#x2013;4152. doi: 10.1093/hmg/ddx301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx301</ArticleId><ArticleId IdType="pubmed">28973294</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenas A., Chen J., Kuang L., Barnett K.R., Kasarskis E.J., Gal J., Zhu H. Lysine acetylation regulates the RNA binding, subcellular localization and inclusion formation of FUS. Hum. Mol. Genet. 2020;29:2684&#x2013;2697. doi: 10.1093/hmg/ddaa159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddaa159</ArticleId><ArticleId IdType="pmc">PMC7530527</ArticleId><ArticleId IdType="pubmed">32691043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou C., Synan M.J., Li J., Xiong S., Manni M.L., Liu Y., Chen B.B., Zhao Y., Shiva S., Tyurina Y.Y., et al. LPS impairs oxygen utilization in epithelia by triggering degradation of the mitochondrial enzyme Alcat1. J. Cell Sci. 2016;129:51&#x2013;64. doi: 10.1242/jcs.176701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.176701</ArticleId><ArticleId IdType="pmc">PMC4732295</ArticleId><ArticleId IdType="pubmed">26604221</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y., Cao R., Ding G., Hong S., Zhou W., Lu W., Damle M., Fang B., Wang C.C., Qian J., et al. Integrated omics approaches to characterize a nuclear receptor corepressor-associated histone deacetylase in mouse skeletal muscle. Mol. Cell Endocrinol. 2018;471:22&#x2013;32. doi: 10.1016/j.mce.2017.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2017.05.024</ArticleId><ArticleId IdType="pmc">PMC5702591</ArticleId><ArticleId IdType="pubmed">28554803</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Li L., Lin W.L., Dickson D.W., Petrucelli L., Zhang T., Wang X. The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum. Mol. Genet. 2013;22:4706&#x2013;4719. doi: 10.1093/hmg/ddt319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt319</ArticleId><ArticleId IdType="pmc">PMC3820133</ArticleId><ArticleId IdType="pubmed">23827948</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonneaud A., Turgeon N., Jones C., Couture C., Levesque D., Boisvert F.M., Boudreau F., Asselin C. HDAC1 and HDAC2 independently regulate common and specific intrinsic responses in murine enteroids. Sci. Rep. 2019;9:5363. doi: 10.1038/s41598-019-41842-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41842-6</ArticleId><ArticleId IdType="pmc">PMC6441098</ArticleId><ArticleId IdType="pubmed">30926862</ArticleId></ArticleIdList></Reference><Reference><Citation>Galmozzi A., Mitro N., Ferrari A., Gers E., Gilardi F., Godio C., Cermenati G., Gualerzi A., Donetti E., Rotili D., et al. Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Diabetes. 2013;62:732&#x2013;742. doi: 10.2337/db12-0548.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db12-0548</ArticleId><ArticleId IdType="pmc">PMC3581211</ArticleId><ArticleId IdType="pubmed">23069623</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X., Ye X., Guo W., Lu H., Gao Z. Inhibition of HDAC3 promotes ligand-independent PPARgamma activation by protein acetylation. J. Mol. Endocrinol. 2014;53:191&#x2013;200. doi: 10.1530/JME-14-0066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JME-14-0066</ArticleId><ArticleId IdType="pmc">PMC4391273</ArticleId><ArticleId IdType="pubmed">24982244</ArticleId></ArticleIdList></Reference><Reference><Citation>Knutson S.K., Chyla B.J., Amann J.M., Bhaskara S., Huppert S.S., Hiebert S.W. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J. 2008;27:1017&#x2013;1028. doi: 10.1038/emboj.2008.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2008.51</ArticleId><ArticleId IdType="pmc">PMC2323257</ArticleId><ArticleId IdType="pubmed">18354499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S., Zhou W., Fang B., Lu W., Loro E., Damle M., Ding G., Jager J., Zhang S., Zhang Y., et al. Dissociation of muscle insulin sensitivity from exercise endurance in mice by HDAC3 depletion. Nat. Med. 2017;23:223&#x2013;234. doi: 10.1038/nm.4245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4245</ArticleId><ArticleId IdType="pmc">PMC5540654</ArticleId><ArticleId IdType="pubmed">27991918</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S., Wen Y., Tong H., Loro E., Gong Y., Liu J., Hong S., Li L., Khurana T.S., Chu M., et al. The HDAC3 enzymatic activity regulates skeletal muscle fuel metabolism. J. Mol. Cell. Biol. 2019;11:133&#x2013;143. doi: 10.1093/jmcb/mjy066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mjy066</ArticleId><ArticleId IdType="pmc">PMC6392100</ArticleId><ArticleId IdType="pubmed">30428023</ArticleId></ArticleIdList></Reference><Reference><Citation>Palamiuc L., Schlagowski A., Ngo S.T., Vernay A., Dirrig-Grosch S., Henriques A., Boutillier A.L., Zoll J., Echaniz-Laguna A., Loeffler J.P., et al. A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol. Med. 2015;7:526&#x2013;546. doi: 10.15252/emmm.201404433.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201404433</ArticleId><ArticleId IdType="pmc">PMC4492815</ArticleId><ArticleId IdType="pubmed">25820275</ArticleId></ArticleIdList></Reference><Reference><Citation>Area-Gomez E., Larrea D., Yun T., Xu Y., Hupf J., Zandkarimi F., Chan R.B., Mitsumoto H. Lipidomics study of plasma from patients suggest that ALS and PLS are part of a continuum of motor neuron disorders. Sci. Rep. 2021;11:13562. doi: 10.1038/s41598-021-92112-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-92112-3</ArticleId><ArticleId IdType="pmc">PMC8245424</ArticleId><ArticleId IdType="pubmed">34193885</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahy E., Subramaniam S., Murphy R.C., Nishijima M., Raetz C.R., Shimizu T., Spener F., van Meer G., Wakelam M.J., Dennis E.A. Update of the LIPID MAPS comprehensive classification system for lipids1. J. Lipid Res. 2009;50:S9&#x2013;S14. doi: 10.1194/jlr.R800095-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R800095-JLR200</ArticleId><ArticleId IdType="pmc">PMC2674711</ArticleId><ArticleId IdType="pubmed">19098281</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampaio J.L., Gerl M.J., Klose C., Ejsing C.S., Beug H., Simons K., Shevchenko A. Membrane lipidome of an epithelial cell line. Proc. Natl. Acad. Sci. USA. 2011;108:1903&#x2013;1907. doi: 10.1073/pnas.1019267108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1019267108</ArticleId><ArticleId IdType="pmc">PMC3033259</ArticleId><ArticleId IdType="pubmed">21245337</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejsing C.S., Sampaio J.L., Surendranath V., Duchoslav E., Ekroos K., Klemm R.W., Simons K., Shevchenko A. Global analysis of the yeast lipidome by quantitative shotgun mass spectrometry. Proc. Natl. Acad. Sci. USA. 2009;106:2136&#x2013;2141. doi: 10.1073/pnas.0811700106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0811700106</ArticleId><ArticleId IdType="pmc">PMC2650121</ArticleId><ArticleId IdType="pubmed">19174513</ArticleId></ArticleIdList></Reference><Reference><Citation>Surma M.A., Herzog R., Vasilj A., Klose C., Christinat N., Morin-Rivron D., Simons K., Masoodi M., Sampaio J.L. An automated shotgun lipidomics platform for high throughput, comprehensive, and quantitative analysis of blood plasma intact lipids. Eur. J. Lipid Sci. Technol. 2015;117:1540&#x2013;1549. doi: 10.1002/ejlt.201500145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejlt.201500145</ArticleId><ArticleId IdType="pmc">PMC4606567</ArticleId><ArticleId IdType="pubmed">26494980</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog R., Schuhmann K., Schwudke D., Sampaio J.L., Bornstein S.R., Schroeder M., Shevchenko A. LipidXplorer: A software for consensual cross-platform lipidomics. PLoS ONE. 2012;7:e29851. doi: 10.1371/journal.pone.0029851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029851</ArticleId><ArticleId IdType="pmc">PMC3260173</ArticleId><ArticleId IdType="pubmed">22272252</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog R., Schwudke D., Schuhmann K., Sampaio J.L., Bornstein S.R., Schroeder M., Shevchenko A. A novel informatics concept for high-throughput shotgun lipidomics based on the molecular fragmentation query language. Genome Biol. 2011;12:1&#x2013;25. doi: 10.1186/gb-2011-12-1-r8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2011-12-1-r8</ArticleId><ArticleId IdType="pmc">PMC3091306</ArticleId><ArticleId IdType="pubmed">21247462</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong J., Wishart D.S., Xia J. Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis. Curr. Protoc. Bioinform. 2019;68:e86. doi: 10.1002/cpbi.86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpbi.86</ArticleId><ArticleId IdType="pubmed">31756036</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner F. GO-PCA: An Unsupervised Method to Explore Gene Expression Data Using Prior Knowledge. PLoS ONE. 2015;10:e0143196. doi: 10.1371/journal.pone.0143196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0143196</ArticleId><ArticleId IdType="pmc">PMC4648502</ArticleId><ArticleId IdType="pubmed">26575370</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>